Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Dabigatran Etexilate	26,199
Overall Study	STARTED	Warfarin	70,071
Overall Study	STARTED	Rivaroxaban	32,595
Overall Study	STARTED	Apixaban	11,322
Overall Study	COMPLETED	Dabigatran Etexilate	1,130
Overall Study	COMPLETED	Warfarin	2,566
Overall Study	COMPLETED	Rivaroxaban	1,602
Overall Study	COMPLETED	Apixaban	637
Overall Study	NOT COMPLETED	Dabigatran Etexilate	25,069
Overall Study	NOT COMPLETED	Warfarin	67,505
Overall Study	NOT COMPLETED	Rivaroxaban	30,993
Overall Study	NOT COMPLETED	Apixaban	10,685

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03006341/flow